The European Commission (EC) has issued a marketing authorisation for Sanofi Genzyme’s therapy Nexviadyme (avalglucosidase alfa) for the long-term treatment of both late-onset and infantile-onset Pompe disease.
Pompe disease is a rare, progressive and debilitating muscle disorder which can present as infantile-onset Pompe disease (IOPD), the most severe form of the disease with rapid onset in infancy, or as late-onset Pompe disease (LOPD), which results in progressive muscle damage.
![Het beste uit je content halen met een kloppend verhaal [10 stappen]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/businesswoman-working-at-creative-office-2023-11-27-05-24-05-utc-1-80x60.jpg)
